ProSomnus® Enrolls First Participant in Study Evaluating Safety and Efficacy of ProSomnus EVO™ in Treating Severe Obstructive Sleep Apnea
19 déc. 2022 08h00 HE
|
ProSomnus Sleep Technologies, Inc.
SAN FRANCISCO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today...
ProSomnus® Announces Medicare Reimbursement for ProSomnus EVO® [PH] Sleep Apnea and Snoring Device
15 déc. 2022 08h00 HE
|
ProSomnus Sleep Technologies, Inc.
SAN FRANCISCO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision oral appliance therapy (OAT) for the treatment of Obstructive Sleep Apnea...
Study Published in "Military Medicine" Reports 88% Success Treating Obstructive Sleep Apnea Patients with Precision Oral Appliance Therapy
08 déc. 2022 08h00 HE
|
ProSomnus Sleep Technologies, Inc.
Treatment with Precision Oral Appliance Therapy Demonstrated Significant Improvements in Apnea-Hypopnea Events, Respiratory Disturbances, Oxygen Saturation, REM Sleep, Sleep Efficiency and Sleepiness ...
ProSomnus® Debuts as Publicly Traded Company Focused on Disrupting Obstructive Sleep Apnea Treatment Market with Patient-preferred Precision Oral Appliance Therapy Devices
06 déc. 2022 17h55 HE
|
ProSomnus Sleep Technologies, Inc.
Completes business combination with Lakeshore Acquisition I Corp. ProSomnus common stock will trade on Nasdaq Capital Market under ticker symbol “OSA” SAN FRANCISCO, Dec. 06, 2022 (GLOBE NEWSWIRE)...
ProSomnus Reports Third Quarter Financial Results and Provides Corporate Update
29 nov. 2022 08h30 HE
|
ProSomnus Sleep Technologies, Inc.
Generated record quarterly revenues, and expects merger with Lakeshore Acquisition I Corp. to close in the fourth quarter of 2022 Company Updates 2022 Revenue Guidance to range of $19.0 - $19.5...
ProSomnus® Announces FDA 510(k) Clearance for ProSomnus EVO™ [PH] Sleep and Snore Device
02 nov. 2022 08h30 HE
|
ProSomnus Sleep Technologies, Inc.
Device expands ProSomnus’ suite of FDA-cleared Precision Oral Appliance Therapy Devices for treatment of Obstructive Sleep Apnea (OSA) Device is engineered to provide Medicare beneficiaries and...
ProSomnus® Sleep Technologies to Participate at the Oppenheimer Private Company Showcase
05 oct. 2022 09h00 HE
|
ProSomnus Sleep Technologies, Inc.
SAN FRANCISCO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- ProSomnus Holdings Inc. (“ProSomnus”), the leader in patient preferred medical devices for the treatment of obstructive sleep apnea (OSA), today...
ProSomnus® Announces Availability of Insurance Reimbursement for Oral Appliance Therapy Devices in Germany
15 sept. 2022 18h03 HE
|
ProSomnus Sleep Technologies, Inc.
SAN FRANCISCO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- ProSomnus, a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced that the ProSomnus EVOTM Sleep...
ProSomnus Named to Inc. 5000 List of Fastest-Growing Companies for Fourth Consecutive Year
16 août 2022 16h05 HE
|
ProSomnus Sleep Technologies, Inc.
SAN FRANCISCO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- ProSomnus (“the Company”), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced that it has...
ProSomnus® to Host First Annual ProSleep Users Conference
29 juil. 2022 08h00 HE
|
ProSomnus Sleep Technologies, Inc.
SAN FRANCISCO, July 29, 2022 (GLOBE NEWSWIRE) -- ProSomnus, a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced it will host a first of its...